• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞因子风暴:COVID-19 恶化的病理生理演变的主要决定因素。

Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration.

机构信息

Department of Cardiology, Heart Center, Zhujiang Hospital, Southern Medical University/The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.

Department of Neurology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

出版信息

Front Immunol. 2021 Apr 28;12:589095. doi: 10.3389/fimmu.2021.589095. eCollection 2021.

DOI:10.3389/fimmu.2021.589095
PMID:33995341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8115911/
Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing major threat to global health and has posed significant challenges for the treatment of severely ill COVID-19 patients. Several studies have reported that cytokine storms are an important cause of disease deterioration and death in COVID-19 patients. Consequently, it is important to understand the specific pathophysiological processes underlying how cytokine storms promote the deterioration of COVID-19. Here, we outline the pathophysiological processes through which cytokine storms contribute to the deterioration of SARS-CoV-2 infection and describe the interaction between SARS-CoV-2 and the immune system, as well as the pathophysiology of immune response dysfunction that leads to acute respiratory distress syndrome (ARDS), multi-organ dysfunction syndrome (MODS), and coagulation impairment. Treatments based on inhibiting cytokine storm-induced deterioration and occurrence are also described.

摘要

新型严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 引起的 2019 年冠状病毒病 (COVID-19) 大流行是对全球健康的持续重大威胁,给重症 COVID-19 患者的治疗带来了重大挑战。有几项研究报告称,细胞因子风暴是 COVID-19 患者病情恶化和死亡的一个重要原因。因此,了解细胞因子风暴如何促进 COVID-19 恶化的具体病理生理过程非常重要。在这里,我们概述了细胞因子风暴导致 SARS-CoV-2 感染恶化的病理生理过程,并描述了 SARS-CoV-2 与免疫系统的相互作用,以及导致急性呼吸窘迫综合征 (ARDS)、多器官功能障碍综合征 (MODS) 和凝血功能障碍的免疫反应功能障碍的病理生理学。还描述了基于抑制细胞因子风暴诱导的恶化和发生的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b0/8115911/6db0b985c480/fimmu-12-589095-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b0/8115911/dff4b5cb02aa/fimmu-12-589095-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b0/8115911/e9cb823e485c/fimmu-12-589095-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b0/8115911/6db0b985c480/fimmu-12-589095-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b0/8115911/dff4b5cb02aa/fimmu-12-589095-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b0/8115911/e9cb823e485c/fimmu-12-589095-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b0/8115911/6db0b985c480/fimmu-12-589095-g003.jpg

相似文献

1
Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration.细胞因子风暴:COVID-19 恶化的病理生理演变的主要决定因素。
Front Immunol. 2021 Apr 28;12:589095. doi: 10.3389/fimmu.2021.589095. eCollection 2021.
2
COVID-19 and inflammatory bowel disease: A pathophysiological assessment.COVID-19 与炎症性肠病:病理生理学评估。
Biomed Pharmacother. 2021 Mar;135:111233. doi: 10.1016/j.biopha.2021.111233. Epub 2021 Jan 5.
3
Controlling Cytokine Storm Is Vital in COVID-19.控制细胞因子风暴是防治 COVID-19 的关键。
Front Immunol. 2020 Nov 30;11:570993. doi: 10.3389/fimmu.2020.570993. eCollection 2020.
4
Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword.细胞因子风暴与 COVID-19:一把双刃剑。
Front Immunol. 2021 Sep 30;12:742941. doi: 10.3389/fimmu.2021.742941. eCollection 2021.
5
Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.固有受体激活模式涉及 COVID-19、ALI/ARDS 和脓毒症细胞因子风暴中的 TLR 和 NLR 协同作用:综述和模型制作新的预测和治疗建议。
Int J Mol Sci. 2021 Feb 20;22(4):2108. doi: 10.3390/ijms22042108.
6
SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients.SARS-CoV-2 引起的细胞因子反应与其他严重感染患者中导致细胞因子风暴的呼吸道病毒不同。
Front Immunol. 2021 Mar 1;12:629193. doi: 10.3389/fimmu.2021.629193. eCollection 2021.
7
in COVID-19 Infection: Immunopathogenesis and Possible Therapeutic Perspective.在 COVID-19 感染:免疫发病机制和可能的治疗视角中。
Viral Immunol. 2021 Dec;34(10):679-688. doi: 10.1089/vim.2021.0071. Epub 2021 Dec 8.
8
Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.β 受体阻滞剂对新冠病毒感染中交感神经和细胞因子风暴的影响。
Front Immunol. 2021 Nov 11;12:749291. doi: 10.3389/fimmu.2021.749291. eCollection 2021.
9
Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.托珠单抗在 SARS-CoV-2 诱导的细胞因子风暴中的治疗作用:原理和现有证据。
Int J Mol Sci. 2021 Mar 17;22(6):3059. doi: 10.3390/ijms22063059.
10
Immune Responses to the Novel Coronavirus-2: Friend or Foe?对新型冠状病毒2的免疫反应:是福还是祸?
Immunol Invest. 2021 Nov;50(8):949-951. doi: 10.1080/08820139.2020.1795191. Epub 2020 Jul 21.

引用本文的文献

1
SARS-CoV-2 Pneumonia: Advances in Diagnosis and Treatment.严重急性呼吸综合征冠状病毒2型肺炎:诊断与治疗进展
Microorganisms. 2025 Jul 31;13(8):1791. doi: 10.3390/microorganisms13081791.
2
Alarming implications: severe fever with thrombocytopenia syndrome and its biological vectors in the context of climate change.警示意义:气候变化背景下的严重发热伴血小板减少综合征及其生物媒介
Front Microbiol. 2025 Jul 25;16:1544427. doi: 10.3389/fmicb.2025.1544427. eCollection 2025.
3
The ACE2 decoy receptor can overcome immune escape by rapid mutating SARS-CoV-2 variants and reduce cytokine induction and clot formation.

本文引用的文献

1
A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms.关于用于重症新型冠状病毒肺炎以预防细胞因子风暴的全身性皮质类固醇激素的作用及副作用的综述
EXCLI J. 2021 Feb 15;20:339-365. doi: 10.17179/excli2020-3196. eCollection 2021.
2
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.科维希尔德腺病毒载体新冠疫苗(ChAdOx1 nCoV-19)对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.
3
Impact of Systemic Corticosteroids on Mortality in Older Adults With Critical COVID-19 Pneumonia.
血管紧张素转换酶2(ACE2)诱饵受体可以通过快速突变的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体克服免疫逃逸,并减少细胞因子诱导和血栓形成。
J Biomed Sci. 2025 Jun 26;32(1):59. doi: 10.1186/s12929-025-01156-4.
4
cfDNA methylation detection as potential liquid biopsy of multiple organ injury in myocarditis patients.循环游离DNA甲基化检测作为心肌炎患者多器官损伤潜在的液体活检方法
Clin Epigenetics. 2025 Jun 19;17(1):106. doi: 10.1186/s13148-025-01914-z.
5
Profile of Cytokines Associated with SARS-CoV2 Seropositivity in Multiple Sclerosis Patients and Its Persistence over Six Months.多发性硬化症患者中与新冠病毒血清阳性相关的细胞因子概况及其六个月内的持续性
J Clin Med. 2025 May 26;14(11):3736. doi: 10.3390/jcm14113736.
6
Biomarker Patterns and Their Association with Lung Injury in COVID-19 Patients.新型冠状病毒肺炎患者的生物标志物模式及其与肺损伤的关联
Medicina (Kaunas). 2025 May 21;61(5):931. doi: 10.3390/medicina61050931.
7
Targeting mTOR in myeloid cells prevents infection-associated inflammation.靶向髓系细胞中的mTOR可预防感染相关炎症。
iScience. 2025 Mar 4;28(4):112163. doi: 10.1016/j.isci.2025.112163. eCollection 2025 Apr 18.
8
Amniotic fluid-derived mesenchymal stem cells as a therapeutic tool against cytokine storm: a comparison with umbilical cord counterparts.羊水来源的间充质干细胞作为对抗细胞因子风暴的治疗工具:与脐带来源的间充质干细胞的比较
Stem Cell Res Ther. 2025 Mar 28;16(1):151. doi: 10.1186/s13287-025-04262-0.
9
Autoantibodies as potential prognostic factors for clinical outcomes related to COVID-19: a systematic review of inception prospective cohort studies with GRADE recommendations.自身抗体作为与2019冠状病毒病相关临床结局的潜在预后因素:一项对起始前瞻性队列研究的系统评价及GRADE推荐意见
Braz J Med Biol Res. 2025 Jan 31;58:e13965. doi: 10.1590/1414-431X2024e13965. eCollection 2025.
10
A stretchable human lung-on-chip model of alveolar inflammation for evaluating anti-inflammatory drug response.一种用于评估抗炎药物反应的可拉伸肺泡炎症人肺芯片模型。
Bioeng Transl Med. 2024 Sep 5;10(1):e10715. doi: 10.1002/btm2.10715. eCollection 2025 Jan.
全身性皮质类固醇对重症新型冠状病毒肺炎老年患者死亡率的影响。
J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):e127-e132. doi: 10.1093/gerona/glab074.
4
Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines.用于对抗 SARS-CoV-2 感染的有效药物和当前疫苗的状况。
Biomed Pharmacother. 2021 May;137:111330. doi: 10.1016/j.biopha.2021.111330. Epub 2021 Jan 28.
5
DNA vaccines against COVID-19: Perspectives and challenges.针对 COVID-19 的 DNA 疫苗:观点与挑战。
Life Sci. 2021 Feb 15;267:118919. doi: 10.1016/j.lfs.2020.118919. Epub 2020 Dec 19.
6
Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study.沙利度胺联合短期小剂量糖皮质激素治疗重症 COVID-19:一项病例系列研究。
Int J Infect Dis. 2021 Feb;103:507-513. doi: 10.1016/j.ijid.2020.12.023. Epub 2020 Dec 14.
7
Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes.TNF-α 和 IFN-γ 的协同作用可引发 SARS-CoV-2 感染和细胞因子休克综合征中的炎症细胞死亡、组织损伤和死亡。
Cell. 2021 Jan 7;184(1):149-168.e17. doi: 10.1016/j.cell.2020.11.025. Epub 2020 Nov 19.
8
Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques.感染 SARS-CoV-2 的恒河猴中的血管疾病和血栓形成。
Cell. 2020 Nov 25;183(5):1354-1366.e13. doi: 10.1016/j.cell.2020.10.005. Epub 2020 Oct 9.
9
The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series.新冠肺炎患者恢复期血浆疗法的疗效评估:一项多中心病例系列研究。
Signal Transduct Target Ther. 2020 Oct 6;5(1):219. doi: 10.1038/s41392-020-00329-x.
10
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.mRNA 疫苗对 SARS-CoV-2 的作用-初步报告。
N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.